NUA Surgical is an Irish based, VC backed start-up with global ambitions to improve maternal healthcare. Its flagship product is the SteriCISION® C-Section Retractor, designed to enhance the visualisation and access to the uterus during caesarean delivery, thus reducing risk factors that lead to many of the most frequent intra-operative and post-operative maternal complications. With a vision focused on safer births, better outcomes for mothers and babies, and improved instruments for surgical teams, NUA Surgical’s structured progression—from needs led innovation and grant funded research to robust pre clinical validation, quality driven product development, institutional recognition and substantial Series A financing—demonstrates a consistent commitment to continuous improvement and best practice in the medical device industry. In the last 24 months the team at NUA Surgical has expanded from three founders to a team of fourteen spanning three continents and have made very significant progress towards deepening its intellectual property portfolio and advancing its flagship product SteriCISION®, through preclinical testing towards a first in human studies.  Securing a Series A investment led by international investors, has both provided validation of the business case and strengthened the team to advance the SteriCISION® product through regulatory approval and onto the market in 2027.With 30M C-Sections each year, it is the most frequent major surgery in the world, however a lack of innovation in this space has left obstetricians struggling to gain suitable access and visualization of the uterus, leading to longer, more complicated surgeries and resulting in increased risk of haemorrhage, infection and even death as opposed to a vaginal birth. These complications also lead to delayed healing times, increased length of hospital stays and associated costs. Furthermore, the obesity epidemic is magnifying the risk of complications in this surgery.  This unmet clinical need was identified by NUA Surgical CEO, Barry McCann, when he spent time in clinical immersion in operating theatres, during the BioInnovate Ireland Fellowship Programme in 2018.  He felt compelled to do better for patients and their physicians, and this has led to the creation of SteriCISION®, which is the lead product of NUA Surgical. SteriCISION® is a self-retaining, single-use surgical tool which is designed to enhance the visualisation and access to the uterus during caesarean delivery.  NUA Surgical is led by a founding team with over 65 years of industry experience spanning commercial, technical and design control. The expanded team spans three continents and have backgrounds from some of the most respected healthcare brands worldwide. From initial public grant funding, the company progressed to raising approximately €2.3 million prior to Series A, supporting early team build out and iterative R&D in collaboration with clinical partners. In December 2024, NUA Surgical secured a €6.5 million Series A investment round to drive manufacturing, testing, regulatory clearance and early commercialisation of SteriCISION, including the establishment of manufacturing in Ireland and expansion of the team. NUA Surgical received High Potential Start-Up status from Enterprise Ireland upon spinning out of the University and has since been recognized around the world as a start-up to watch, highlighting the strength of its innovation and its alignment with global healthcare priorities. The company has won multiple awards on national and international stages, including success at the Irish National Start-Up Awards, National HealthTech Innovation Awards, Global Maternal Health Innovation Competition, and recognition as the Emerging MedTech Company of the Year by the Irish MedTech Association, underscoring peer reviewed excellence in innovation, quality and execution. Since 2019, NUA Surgical has built a strong IP portfolio reinforcing a long term, defensible position in the global surgical instruments market. This portfolio includes three granted US patents, two granted European patents, granted Chinese, Mexican and Australian patents, and pending patents spanning six continents.